Literature DB >> 25352381

Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?

Fabrizio Vianello1, Giuseppe Cella, Elena Osto, Andrea Ballin, Giulia Famoso, Sara Tellatin, Sabino Iliceto, Umberto Cucchini, Graziella Saggiorato, Elisabetta Omenetto, Francesco Tona.   

Abstract

Myeloproliferative neoplasms are most commonly associated with venous thrombosis. Up to 60% of patients experience a thrombotic event in their lifetimes, including stroke or myocardial infarction. It is unclear whether pathogenetic factors linking essential thrombocythemia (ET) and polycythemia vera (PV) to thrombotic complications do play a role in the risk of coronary artery disease (CAD). We aimed to assess coronary flow reserve (CFR) as a marker of coronary microvascular function in asymptomatic patients with ET and PV. Fifty-two patients with ET (M/F 13/39, age 61 ± 7 years) and 22 patients with PV (M/F 13/9, age 60.4 ± 13 years) without clinical evidence of heart disease, and 50 controls matched for age and gender were studied. None had CAD. All control subjects were asymptomatic with no history of heart disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. In patients with ET and PV, CFR was lower than in controls (2.9 ± 0.94 and 2.2 ± 0.7 vs. 3.8 ± 0.7, P < 0.004 and P < 0.0001 respectively). The prevalence of CFR ≤ 2.5 was higher in patients with ET (20 cases, 38.5%) and PV (15 cases, 68.2%) compared with controls (4.1%) (P < 0.0001). Severe CFR (CFR < 2) impairment was found in eight patients with ET (15.4%), in nine patients with PV (40.9%), and in none of control subjects. The mutation of JAK2 gene was associated with abnormal CFR. Asymptomatic patients with ET and PV have coronary microvascular dysfunction in the absence of clinical conditions suggesting CAD.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25352381     DOI: 10.1002/ajh.23881

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.

Authors:  Toru Inami; Masahiro Okabe; Masato Matsushita; Nobuaki Kobayashi; Koiti Inokuchi; Noritake Hata; Yoshihiko Seino; Wataru Shimizu
Journal:  Heart Vessels       Date:  2016-01-29       Impact factor: 2.037

Review 2.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

3.  The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

Authors:  Chiara Baldini; Francesca Romana Moriconi; Sara Galimberti; Peter Libby; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2021-11-07       Impact factor: 35.855

4.  What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations.

Authors:  Marie-Camille Soucy-Giguère; Pierre Yves Turgeon; Mario Sénéchal
Journal:  Int Med Case Rep J       Date:  2019-08-08

5.  Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.

Authors:  Mirjana Gotic; Miklos Egyed; Liana Gercheva; Krzysztof Warzocha; Hans Michael Kvasnicka; Heinrich Achenbach; Jingyang Wu
Journal:  Cardiovasc Toxicol       Date:  2020-10-29       Impact factor: 3.231

Review 6.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.